Conditions & Treatments
Explore conditions treatable with peptide therapy, testosterone replacement therapy, and GLP-1 medications. Each page covers symptoms, causes, and available treatment options.
Hormonal
Low Testosterone
Low testosterone is a clinical condition in which the body produces insufficient testosterone, the primary male sex hormone. It affects roughly 40% of men over age 45 and becomes more common with each decade of life. Symptoms range from fatigue and reduced libido to loss of muscle mass and increased body fat.
Sexual Dysfunction
Sexual dysfunction includes erectile difficulty, reduced libido, and arousal disorders in both men and women. It is highly prevalent, affecting an estimated 30% of men and 40% of women at some point. Underlying hormonal imbalances are often a root cause and can be addressed through targeted peptide and hormone therapies.
Sleep Disorders
Sleep disorders encompass conditions that impair sleep quality, duration, or architecture, including insomnia, fragmented sleep, and disrupted circadian rhythms. Poor sleep affects roughly one-third of US adults and has cascading effects on hormones, metabolism, cognitive function, and immune health. Addressing the hormonal and neurochemical factors behind poor sleep can produce improvements beyond what sleep hygiene alone achieves.
Growth Hormone Deficiency
Adult growth hormone deficiency is a condition in which the pituitary gland produces insufficient growth hormone, leading to changes in body composition, energy, and overall health. GH production naturally declines with age at a rate of roughly 14% per decade after age 30. Growth hormone-releasing peptides offer a way to stimulate the body's own GH production rather than relying on exogenous hormone replacement.
Hypogonadism
Hypogonadism is the clinical diagnosis for testosterone levels below the established reference range, typically below 300 ng/dL on two separate morning blood draws. It affects an estimated 4 to 5 million American men and can be classified as primary (testicular) or secondary (pituitary/hypothalamic). Treatment depends on whether the patient desires to preserve fertility.
Erectile Dysfunction
Erectile dysfunction is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects over 30 million men in the United States and becomes more common with age. While PDE5 inhibitors address the vascular component, peptide therapies targeting central arousal pathways and hormonal optimization offer complementary approaches.
Adrenal Fatigue
Adrenal fatigue describes a pattern of HPA axis dysfunction in which prolonged stress leads to dysregulated cortisol output, resulting in fatigue, poor stress tolerance, and hormonal imbalance. While not recognized as a formal medical diagnosis by all endocrinology organizations, the underlying HPA axis dysfunction and its symptoms are well-documented in clinical practice. Treatment focuses on restoring normal cortisol rhythms and supporting the stress response system.
Recovery
Muscle Recovery
Muscle recovery refers to the body's process of repairing damaged muscle fibers after exercise, injury, or surgery. Slow recovery limits training frequency and athletic progress. Peptide therapies targeting tissue repair pathways can accelerate this process by reducing inflammation and promoting cellular regeneration.
Gut Inflammation
Gut inflammation encompasses chronic inflammatory conditions of the gastrointestinal tract, including increased intestinal permeability (commonly called leaky gut) and IBS-related symptoms. These conditions affect an estimated 10 to 15% of the global population. Restoring the gut lining and reducing local inflammation are the primary therapeutic goals.
Joint Pain
Chronic joint pain results from cartilage degradation, inflammation, or repetitive injury to the connective tissues surrounding joints. It is one of the most common reasons adults seek medical care, affecting over 50 million Americans. Peptide-based approaches focus on reducing inflammation and promoting connective tissue repair at the cellular level.
Sarcopenia
Sarcopenia is the progressive loss of skeletal muscle mass, strength, and function that occurs with aging. It typically begins around age 30 with a loss of 3 to 5% of muscle mass per decade, accelerating after age 60. Growth hormone-releasing peptides and resistance training are the primary interventions studied for preventing and reversing this condition.
Post-Surgical Recovery
Post-surgical recovery involves the body's healing response after a surgical procedure, including wound closure, tissue remodeling, and restoration of function. Recovery timelines vary significantly depending on the procedure, the patient's age, and baseline health. Tissue-repair peptides are being studied for their potential to accelerate healing and reduce complications during this critical window.
Skin Aging
Skin aging is the progressive loss of collagen, elastin, and hyaluronic acid that leads to wrinkles, sagging, and reduced skin thickness. Intrinsic aging begins in the mid-20s, with collagen production declining approximately 1% per year after age 30. Peptides targeting collagen synthesis and cellular turnover offer a research-backed approach to supporting skin health from the inside out.
Tendon Injury
Tendon injuries include tendinopathy, partial tears, and complete ruptures of the fibrous tissue connecting muscle to bone. Tendons have limited blood supply, which makes them slow to heal compared to other tissues. Repair-focused peptides that promote angiogenesis and collagen synthesis are being studied to address this fundamental limitation in tendon healing biology.
Neuropathy
Neuropathy is damage to peripheral nerves causing pain, numbness, tingling, and weakness, most commonly in the hands and feet. Diabetic neuropathy alone affects roughly 50% of people with diabetes. Nerve tissue has limited regenerative capacity, making neuroprotective and neuroregenerative compounds an active area of research for improving outcomes in these patients.
Metabolic
Weight Loss Plateau
A weight loss plateau occurs when the body adapts to a caloric deficit by reducing metabolic rate, halting further fat loss despite continued dietary restriction. This is a common experience affecting most people who sustain a caloric deficit for more than 8 to 12 weeks. Addressing the plateau often requires adjusting the metabolic approach rather than simply cutting more calories.
Chronic Fatigue
Chronic fatigue is persistent exhaustion lasting more than six months that is not resolved by sleep or rest. It affects an estimated 836,000 to 2.5 million Americans. The condition often involves mitochondrial dysfunction, hormonal imbalances, or immune dysregulation that require targeted intervention beyond standard lifestyle changes.
Insulin Resistance
Insulin resistance is a metabolic condition in which cells fail to respond normally to insulin, forcing the pancreas to produce more insulin to maintain blood sugar control. It is a precursor to type 2 diabetes and affects over 40% of adults aged 18 to 44 in the United States. GLP-1 receptor agonists and metabolic peptides are among the most effective interventions studied for this condition.
Metabolic Syndrome
Metabolic syndrome is a cluster of interconnected conditions including high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol levels. A person is diagnosed when they meet three or more of these criteria. It affects roughly one-third of US adults and significantly increases the risk of heart disease, stroke, and type 2 diabetes.
Obesity
Obesity is a chronic metabolic disease defined by a BMI of 30 or higher, characterized by excess adipose tissue that increases the risk of numerous health conditions. It affects over 42% of US adults and is driven by a complex interaction of genetics, hormones, behavior, and environment. GLP-1 receptor agonists have transformed obesity treatment by producing clinically significant weight loss in large-scale trials.
Type 2 Diabetes
Type 2 diabetes is a chronic metabolic condition in which the body becomes resistant to insulin and the pancreas gradually loses the ability to produce enough insulin to maintain normal blood sugar. It affects over 37 million Americans and is the seventh leading cause of death in the United States. GLP-1 receptor agonists have become a cornerstone of modern diabetes management.
Cognitive
Cognitive Decline
Cognitive decline refers to a measurable reduction in memory, focus, processing speed, or executive function beyond what is expected for a person's age. Mild cognitive impairment affects 12 to 18% of adults over 60. Neuroprotective peptides and NAD+ precursors are being studied for their ability to support neuronal health and cognitive function.
Brain Fog
Brain fog is a colloquial term for a cluster of cognitive symptoms including mental cloudiness, poor concentration, and difficulty thinking clearly. It is not a medical diagnosis itself but rather a symptom of underlying conditions ranging from sleep deprivation and hormonal imbalance to chronic inflammation and nutrient deficiency. Identifying and addressing the root cause is essential for lasting improvement.
Immune
Immune Deficiency
Immune deficiency refers to a weakened immune system that results in frequent infections, slow recovery from illness, and reduced ability to fight pathogens. While primary immunodeficiencies are genetic, secondary immune weakness is far more common and can result from aging, stress, poor nutrition, or chronic disease. Thymic peptides are being researched for their ability to modulate and strengthen immune function.
Autoimmune Support
Autoimmune conditions occur when the immune system mistakenly attacks the body's own tissues, causing chronic inflammation and organ damage. Over 80 autoimmune diseases have been identified, collectively affecting roughly 24 million Americans. Immune-modulating peptides aim to rebalance immune function rather than broadly suppressing it, offering a more targeted approach to managing these complex conditions.